Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Herbert Y. Meltzer,Roger Mills,Stephen Revell,Hilde Williams,Ann Johnson,Daun Bahr,Joseph H. Friedman +6 more
TLDR
Pimavanserin showed significantly greater improvement in psychosis in patients with PDP at a dose which did not impair motor function, or cause sedation or hypotension, which support the hypothesis that attenuation of psychosis secondary to DA receptor stimulation in PDP may be achieved through selective 5-HT2A receptor antagonism.About:
This article is published in Neuropsychopharmacology.The article was published on 2010-03-01 and is currently open access. It has received 241 citations till now. The article focuses on the topics: Pimavanserin & Psychosis.read more
Citations
More filters
Journal ArticleDOI
Therapeutics of Alzheimer's disease: Past, present and future.
TL;DR: The current rationales and targets evaluated for therapeutic benefit in AD are reviewed and the major developments in this direction are the amyloid and tau based therapeutics, which could hold the key to treatment of AD in the near future.
Journal ArticleDOI
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review
Klaus Seppi,K. Ray Chaudhuri,Miguel Coelho,Susan H. Fox,Regina Katzenschlager,Santiago Perez Lloret,Daniel Weintraub,Daniel Weintraub,Cristina Sampaio,Cristina Sampaio +9 more
TL;DR: To update evidence‐based medicine recommendations for treating nonmotor symptoms in Parkinson's disease, the World Health Organization (WHO) selected Austria as a preferred destination for research and clinical trials.
Journal ArticleDOI
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey L. Cummings,Stuart Isaacson,Roger Mills,Hilde Williams,Kathy Chi-Burris,Anne Corbett,Rohit Dhall,Clive Ballard +7 more
TL;DR: Pimavanserin was well tolerated with no significant safety concerns or worsening of motor function and may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist.
Journal ArticleDOI
Priorities in Parkinson's disease research
Wassilios G. Meissner,Wassilios G. Meissner,Mark Frasier,Thomas Gasser,Christopher G. Goetz,Andres M. Lozano,Paola Piccini,Jose A. Obeso,Olivier Rascol,Anthony H.V. Schapira,Valerie Voon,David M. Weiner,François Tison,François Tison,Erwan Bezard +14 more
TL;DR: This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address treatment goals of Parkinson's disease.
Journal ArticleDOI
Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future.
TL;DR: An individualized treatment approach which emphasizes careful monitoring and collaborative decision-making in the context of ongoing benefit-risk assessment is outlined, and the potential contribution of pharmacogenomics and other biological markers in optimizing individual treatment and outcome in the future is evaluated.
References
More filters
Journal ArticleDOI
A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
TL;DR: The development and use of a new scale, the Epworth sleepiness scale (ESS), is described, which is a simple, self-administered questionnaire which is shown to provide a measurement of the subject's general level of daytime sleepiness.
Journal ArticleDOI
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Jeffrey L. Cummings,Michael S. Mega,Kevin F. Gray,S. Rosenberg-Thompson,Daniela Carusi,Jeffrey Gornbein +5 more
TL;DR: The NPI has the advantages of evaluating a wider range of psychopathology than existing instruments, soliciting information that may distinguish among different etiologies of dementia, differentiating between severity and frequency of behavioral changes, and minimizing administration time.
Journal ArticleDOI
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.
Christopher G. Goetz,Werner Poewe,Olivier Rascol,Cristina Sampaio,Glenn T. Stebbins,Carl Counsell,Nir Giladi,Robert G. Holloway,Charity G. Moore,Gregor K. Wenning,Melvin D. Yahr,Lisa Seidl +11 more
TL;DR: The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale, which recommends that it be used in its original form for demographic presentation of patient groups and in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria.